Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology

Aleksandra Danielak¹, John L Wallace², Tomasz Brzozowski¹ and Marcin Magierowski¹*

¹Department of Physiology, Jagiellonian University Medical College, Cracow, Poland, ²Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, Canada

Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used classes of drugs and play a pivotal role in the therapy of numerous inflammatory diseases. However, the adverse effects of these drugs, especially when applied chronically, frequently affect gastrointestinal (GI) tract, resulting in ulceration and bleeding, which constitutes a significant limitation in clinical practice. On the other hand, it has been recently discovered that gaseous mediators nitric oxide (NO), hydrogen sulfide (H₂S) and carbon monoxide (CO) contribute to many physiological processes in the GI tract, including the maintenance of GI mucosal barrier integrity. Therefore, based on the possible therapeutic properties of NO, H₂S and CO, a novel NSAIDs with ability to release one or more of those gaseous messengers have been synthesized. Until now, both preclinical and clinical studies have shown promising effects with respect to the anti-inflammatory potency as well as GI-safety of these novel NSAIDs. This review provides an overview of the gaseous mediators-based NSAIDs along with their mechanisms of action, with special emphasis on possible implications for GI mucosal defense mechanisms.

Keywords: hydrogen sulfide, carbon monoxide, nitric oxide, non-steroidal anti-inflammatory drugs, gastrointestinal safety, inflammation

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ketoprofen, naproxen, indomethacin and others, represent one of the most commonly prescribed medications with a wide spectrum of therapeutic effects. Due to their potent analgesic, anti-inflammatory and antipyretic properties they are commonly used to suppress pain, inflammation as well as fever associated with inflammatory diseases including for instance rheumatoid arthritis and osteoarthritis (Bacchi et al., 2012). Additionally, aspirin, being the most widely used antiplatelet drug, remains crucial in the secondary prevention of cardiovascular diseases (Warner et al., 2011), based on its long-term application (Huang et al., 2011). However, despite considerable advantages of NSAIDs, they are known to exert adverse effects including gastrointestinal (GI) - toxicity, cardiovascular complications and renal failure (Varga et al., 2017). In addition, the risk and panel of complications is further increased by comorbidities and longer time of the NSAIDs treatment, which remains a serious limitation in clinical pharmacotherapy (Harirforoosh et al., 2014). Beneficial and adverse effects of NSAIDs are assumed to result from the inhibition of the enzyme cyclooxygenase (COX), leading to the decreased biosynthesis of prostaglandins (PG), hyperalgesic agents (Bacchi et al.,...
2012). COX is known to exist in two main isoforms – COX-1 and COX-2. COX-1 is constitutively expressed and regulates various physiological functions, whereas COX-2 is considered to be an inducible isoform involved in modulation of pain and inflammatory response under pathological conditions (Conaghan, 2012). However, it should be noted, that this mechanism could be oversimplified in the light of recently published data, showing that COX-2 could be also constitutively expressed in certain tissues of human body (Varga et al., 2017).

GI-adverse effects evoked by NSAIDs are well-documented and involve microbleedings, induction of haemorrhagic lesions, gastroduodenal ulcer formation and even perforations (Lanas, 2010). Two main mechanisms have been implicated in the pathogenesis of these adverse effects, on systemic and local level of NSAIDs activity. The topical action is related to direct toxicity of these compounds toward gastric epithelial cells and mucosal surface, whereas among the systemic effects, the inhibition of PGs biosynthesis leading to an impairment of the organ blood flow is particularly crucial (Wallace, 2008). PGI2 and PGE2, are mainly produced via activity of COX-1 and contribute to the maintenance of gastric mucosal barrier (Konturek, 1985). The following effects have been assumed to be involved in PG-mediated gastroprotection: increased mucosal blood flow, elevated bicarbonate and mucus release, suppression of gastric acid secretion, prevention from leukocyte adherence to the vascular endothelium and downregulation of inflammatory signaling (Wallace, 2008). Therefore, the multifunctional properties of PGs, that embrace both hyperalgesia and GI safety, make this a very challenging prospect to achieve pain and inflammation relief without undesirable GI complications. In recent years many attempts have been undertaken to address this issue and synthesize novel “safer” NSAIDs, which would retain the potent anti-inflammatory action, however, with significantly reduced gastrototoxicity (Sulaieva and Wallace, 2015).

The discovery of second isoform of COX, prompted the development of selective cyclooxygenase-2 inhibitors (coxibs), which were expected to reduce PGs synthesis on the inflammation site, while remaining without such effect in gastric mucosa and thus preserving the potent anti-inflammatory activity with markedly decreased GI-toxicity (Wallace and Muscará, 2001). However, after the enthusiastic introduction of coxibs to the market, serious adverse effects were reported. Although selective COX-2 inhibitors did present improved safety profile in gastric mucosa, generating less ulceration and bleeding, they also exhibited other adverse effects. Precisely, coxibs significantly elevated risk of cardiovascular events such as myocardial infarction, which was a reason for the withdrawal of rofecoxib (Dieppe et al., 2004). This issue raised awareness about important role of COX-2 in the physiological processes in both cardiovascular and renal systems. It has become apparent that inhibition of COX-2 results in suppression of prostacyclin PGI2 synthesis and subsequent imbalance between prothrombotic tromboxane A2 and antithrombotic PGI2, promoting thrombosis and the incidence of cardiovascular events (Mukherjee, 2001). Therefore, despite the preliminary high expectation associated with coxibs and mass promotion of these drugs, they were proved to be of benefit only in a limited group of patients with low risk of cardiovascular death (Topol, 2005).

On the other hand, endogenous gaseous mediators such as nitric oxide (NO), hydrogen sulfide (H₂S) or carbon monoxide (CO) were shown to be involved in the maintenance of GI integrity, to exhibit gastroprotective action, to accelerate ulcer healing and to modulate gastric blood flow and gastro-duodenal secretion. All three molecules were shown to interact each other within GI tract. H₂S-, NO- or CO-releasing pharmacological tools and chemicals were reported to prevent gastric mucosa against the damage induced by exposure of GI-mucosa to stress, ischemia/reperfusion, and the mucosal injury caused by pharmacological agents and drugs such as alendronate or aspirin and other NSAIDs. Therefore, over recent years novel H₂S-, NO- or CO-releasing derivatives of NSAIDs were synthesized (Wallace et al., 2017; Magierowska et al., 2018). Thus, in this review we aimed to provide an update on the recent advances in the development of these novel NSAIDs and their possible molecular mechanisms of action with special emphasis on possible clinical and therapeutic implications.

GASTROENTEROPATHY EVOKED BY NSAIDS

The gastroduodenal toxicity of NSAIDs has been extensively studied so far and the mechanisms beyond it remain largely described. Theoretically, this already recognized pathomechanism of NSAID-induced damage makes these gastric injuries preventable only to limited extent. Gastric acid has been recognized as a crucial pathogenic factor affecting the weakened gastric mucosa due to NSAID-induced PGs inhibition (Wallace, 2012) (Figure 1). Therefore, the histamine H₂ receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), both potent acid secretion suppressors have been clinically recommended in prevention of NSAIDs-induced gastric damage (Scheiman et al., 2006). On the other hand, due to the difficulty in diagnosing of small intestine erosions together with its typically subclinical course, NSAID-induced enteropathy constitutes an under-recognized and underestimated clinical problem (Srinivasan and De Cruz, 2017). Development of the small intestine imaging due to the implementation of the capsule endoscopy, revealed that the prevalence of NSAID-induced small intestine injury is far more frequent than it was initially suspected (Graham et al., 2005). Importantly, the incidence of small intestinal damage among healthy subjects receiving NSAIDs combined with PPI over 2 weeks has been estimated at the level of 55–75% (Goldstein et al., 2005; Maiden et al., 2005; Wallace, 2012). As documented by virtual endoscopy, the small bowel injury may be identified as mucosal erythema, erosions, ulcerations and occult GI bleeding, while clinically these damages are manifested most frequently by iron deficiency anemia (Tai and McAlindon, 2018). Unlike the stomach, there is no proof that gastric acid contributes to the development of intestinal lesions associated with NSAID administration and interestingly, drugs suppressing acid secretion have been shown to even aggravate...
small bowel injuries (Syer et al., 2015; Tai and McAlindon, 2018). Using capsule endoscopy, Watanabe et al. have reported that among rheumatoid patients treated chronically with NSAIDs, the independent risk factors for severe intestinal damage were the age over 65 years and the use of a PPI along with a H2RA (Watanabe et al., 2013).

Interestingly, the mechanisms underlying the pathogenesis of NSAIDs-enteropathy seem to be complex and distinct from those responsible for gastric damage (Boelsterli et al., 2013). The inhibition of PG biosynthesis has been shown to predispose both, gastric and intestinal mucosa to various injurious factors (Figure 1). However, in contrast to NSAIDs gastropathy, the major mechanism responsible for bowel damage appears to be PG-independent (Matsui et al., 2011). Precisely, the enterohepatic circulation of NSAIDs, bile and enteric microbial flora have been all considered as critical pathogenic factors (Syer et al., 2015). Enterohepatic recirculation is assumed to depend upon bacterial β-D-glucuronidase, an enzyme that enhances the resorption of NSAIDs in the ileum, leading in consequence to the harmful re-exposure of the intestinal mucosa to these compounds (Wallace, 2013). Importantly, pharmacological inhibition of bacterial β-glucuronidase has been demonstrated in experimental animal model to reduce the re-exposure of these drugs to intestinal epithelium and thus, remarkably alleviate NSAIDs-induced enteropathy (LoGuidice et al., 2012).

It is also of interest that NSAIDs intake has been shown to elicit significant changes in the quality of enteric microbiota, particularly the elevation in the number of Gram-negative bacteria (Wallace, 2012). The pivotal role of microbiota has been additionally emphasized by the observation that germ-free rats were resistant to the indomethacin-induced enteropathy, and this effect was reversed by intestinal contamination with E.coli (Robert and Asano, 1977). There is also a compelling body of evidence suggesting that the profound suppression of acid secretion by PPIs affect the number and diversity of intestinal bacteria, contributing to the exacerbation of intestinal damage (Bruno et al., 2019). For instance, when a PPI (omeprazole or lansoprazole) was administered to rats in combination with NSAID, the significant alterations in the enteric microbiome profile were identified, especially manifested by the reduction in the Bifidobacterium content, followed by increased severity of intestinal injury (Wallace et al., 2011).

Additionally, bile acid dysmetabolism has been also implicated in the pathogenesis of small bowel damage associated with gastric acid suppression (Blackler et al., 2014). The study by Shindo et al. revealed that the omeprazole treatment in a group of gastric ulcer patients as well as healthy control volunteers resulted in elevated levels of deconjugated bile acids in both groups, which was attributed to the bacterial overgrowth detected in the jejunum (Shindo et al., 1998). Thus, the deconjugation of bile acids due to bacterial enzymatic activity, which is known to enhance the damaging properties of the bile within intestinal epithelium, could also explain the pathogenesis of enteropathy mediated by long-term acid inhibition due to PPI treatment.

To summarize, until now there is no successful strategy being sufficiently proven to offer a fully effective therapeutic approach either in the prevention or in the treatment of NSAIDs gastroenteropathy. Therefore, there is definitely a need for the development of novel effective therapeutic approaches in this field.

![FIGURE 1 | Pathomechanism of NSAIDs-induced gastrointestinal damage.](image-url)
GASEOUS MEDIATORS-RELEASING NSAIDS AND GI TRACT

NO-Releasing NSAIDs
NO is a gaseous mediator involved in the regulation of numerous physiological pathways including those responsible for the homeostasis of the GI tract. NO is endogenously produced within esophageal, gastric and intestinal mucosa via the enzymatic activity of NO synthases:

- neuronal (nNOS), expressed in the neurons of central and peripheral nervous system,
- endothelial (eNOS) located in both endothelial cells and platelets,
- inducible (iNOS), which is expressed in endothelial cells, smooth vascular muscle, neutrophils and macrophages.

Both nNOS and eNOS are constitutive isoforms responsible for the maintenance of GI mucosal defense due to the constant generation of small amounts of NO (Stanek et al., 2008). According to the recent data, the beneficial actions of NO in GI tract include vasodilatation, crucial for the maintenance of blood flow and mucosal barrier integrity, the enhanced epithelial mucus and bicarbonate secretion, the reduced adherence of neutrophils and their infiltration of gastric tissue resulting in diminished reactive oxygen species (ROS) production and decreased oxidative stress (Figure 2) (Magierowski et al., 2015a). Furthermore, NO has been proven to regulate the gastric and intestinal epithelial cells tight junctions through mechanisms involving inhibition of protein and lipid oxidation, modulation of glutathione (GSH/GSSG) ratio, which is crucial for cell survival, and the maintenance of redox homeostasis (Mu et al., 2019). On the other hand, a decrease in NO production has been implicated in the pathogenesis of many diseases including diabetes mellitus, hypertension and arteriosclerosis. Moreover, it has been shown that the pharmacologic inhibition of NO-synthase impaired the healing rate of gastric ulcers (Magierowski et al., 2015).

Based on these physiological and pharmacological properties of NO, a new class of NO-releasing NSAIDs (NO-NSAIDs) was developed by chemically binding a NO-releasing moiety with the parent drug (Fiorucci et al., 2001). Importantly, NO-NSAIDs have been shown to exert anti-inflammatory and analgetic effects comparable or even greater to those provided by conventional NSAIDs with markedly lower GI toxicity (Wallace et al., 1995; Wallace et al., 1999; Al-Swayeh et al., 2000; Kato et al., 2001; Fiorucci et al., 2003; Fiorucci et al., 2004; Rolando et al., 2013). The anti-inflammatory activity of NO-NSAIDs have been proved by adding the NO moiety to various derivatives including aspirin, naproxen, ketoprofen, flurbiprofen, ibuprofen, diclofenac, indomethacin, mesalamine, tolfenamic acid, or celecoxib (Pereira-Leite et al., 2017). It is worth mentioning that NCX-4016 (NO-aspirin) and NCX-530 (NO-indomethacin) have been shown to protect gastric mucosa against HCl/ethanol-induced damage (Takeuchi et al., 1998; Takeuchi et al., 2001). Interestingly, in a rodent model, the administration of NCX-530 vs parent indomethacin did not evoke intestinal damage, and the inhibition of bacterial translocation within intestine with this novel NO-NSAID agent has been proposed to explain this phenomenon (Mizoguchi et al., 2001). Additionally, it has been demonstrated, that the prolonged administration of NO-NSAIDs in contrast to classic parent NSAIDs do not delay, but even accelerate the healing of gastric ulcers (Elliott et al., 1995; Brzozowski et al., 2000; Brzozowska et al., 2004). It should be also noticed, that NCX-4016 and NCX-4215, being another derivative of aspirin releasing NO, have been shown to exert increased antithrombotic activity, comparable to that exhibited by aspirin (Wallace et al., 1995; Momi et al., 2000; Bolla et al., 2006).
These promising results obtained in pre-clinical animal studies provided significant evidence to further explore the assessment of NCX-4016 and nitronaproxen (naproxcinod) in humans. NCX-4016 completed phase 1 clinical trial and entered phase 2, however the further development of this novel NO-NSAID was terminated due to the detected genotoxicity (Di Napoli and Papa, 2003). Naproxcinod successfully completed phase 3 clinical trial and has been shown to be effective in relieving the symptoms of osteoarthritis, while having significantly reduced GI toxicity (Lohmander, 2004; Schnitzer et al., 2005; KARLSSON et al., 2009).

Taking into account that NSAIDs-based pharmacotherapy among elderly diabetic patients correlates with the higher risk of adverse effects such as impaired renal function, excessive fluid retention and aggravated hypertension (Caughhey et al., 2010), NO-NSAIDs seemed to be promising alternative but with one essential adverse effect such as the increased risk of NO-mediated hypotension. Pieper et al. (Pieper et al., 2002) documented in their animal study, the protective effect of chronic NCX-4016 treatment against impaired endothelium-dependent relaxation, which is an important feature of human diabetes mellitus. Similarly, in another report NCX-4016 treatment in the group of diabetic rats resulted in signifi-
cantly reduced vascular endothelium damage (Ambrosini et al., 2005).

Further studies on the usage of NO-NSAID among humans with diabetes are needed to shed more light into the potentially beneficial effects of these novel drugs to counteract some vascular and epithelial aspects of metabolic disorders. Chemical structure of selected NO-NSAIDs are presented on Figure 3.

**H₂S–Releasing NSAIDs**

H₂S, similarly to NO, is an important endogenous gaseous messenger known to modulate the cardiovascular and nervous system functioning, GI defense as well as the inflammatory pathways (Beltowski, 2015). It is produced within human body due to activity of two enzymes: cystathionine-γ-lyase (CTH) and cystathionine-β-synthetase (CBS) (Huang and Moore, 2015). H₂S could be also generated in mitochondria by the activity mercaptopyruvate sulfurtransferase (MPST) (Kimura, 2014). Additionally, this molecule could be produced and metabolized by microbiota within the gut. The endogenous and exogenous H₂S has been recognized as an anti-inflammatory, anti-oxidative and vasodilatory agent, essentially involved in the modulation of inflammatory cascade and the process of resolution of inflammation (Figure 2.) (Wallace, 2010). Furthermore, endogenous and exogenous H₂S released from chemical donors have been implicated in the mechanism of maintenance of gastric mucosal homeostasis and to protect the gastric mucosa against lesions induced by NSAIDs and other noxious factors (Lou et al., 2008; Cipriani et al., 2013; Magierowski et al., 2015; Magierowski et al., 2016; de Araújo et al., 2018; Magierowski et al., 2018). Such a protective effect of H₂S has also been demonstrated in the intestinal mucosa of NSAID-treated rats, which seems to be particularly important due to the current need for an effective therapy against the adverse effects of NSAIDs affecting the intestine (Wallace and Wang, 2015).

A remarkable progress has recently been achieved in the understanding of mechanisms underlying the protective action of H₂S within GI tract, by demonstration that this gaseous molecule enhanced mucosal microcirculation, attenuated the TNF-α signaling along with suppression of pro-inflammatory cytokines expression and leukocyte adherence (Wallace, 2010). Importantly, H₂S released form chemical donors such as NaHS or Lawesson’s reagent, as emphasized by many experimental animal studies, decreased the number and severity of gastric mucosal lesions evoked by NSAIDs, ischemia/reperfusion, ethanol and stress (Zanardo et al., 2006; Mard et al., 2012; Magierowski et al., 2015; Magierowski et al., 2016; Sun et al., 2017; Magierowski et al., 2018).

On the other hand, the inhibition of endogenous H₂S production was associated with remarkably elevated adherence of leukocytes to the vessels wall and with aggravated inflammation accompanying induction of paw edema in rats (Zanardo et al., 2006). The study by Fiorucci et al. (2005) revealed that deleterious gastric adverse effects evoked by NSAIDs may be to some extent ascribed to the suppression of endogenous H₂S biosynthesis, which was documented by a decreased CTH mRNA and protein expression during NSAID treatment.
Therefore, numerous derivatives of H2S-releasing NSAIDs have been developed with improved safety profile of these compounds compared with parent drugs documented in preclinical studies (Magierowski et al., 2015). Promising effects have been achieved with respect to the following novel NSAIDs: H2S-releasing naproxen (ATB-346), H2S-releasing diclofenac (ATB-337 and ACS-15), H2S-releasing ketoprofen (ATB-352) and H2S-releasing aspirin (ATB-340 and ACS-14). Administration of ATB-337 evoked approximately 90% less intestinal damage, when compared to native diclofenac (Wallace et al., 2007). The possible mechanisms responsible for preventive activity of hydrogen sulfide within intestine seem to involve, at least partially, improvement of intestinal barrier, facilitation of antimicrobial immunity and normalization of enteric microbiota profile (Schroeder et al., 2011; Blackler et al., 2015).

Wallace et al. (Wallace et al., 2007) reported that ATB-337 was less gastrotoxic and produced remarkably less injury within gastric as well as intestinal mucosa in rats as compared to its parent drug. Furthermore, ATB-337 was more effective in decreasing of paw edema evoked by carrageenan. Similarly, S-diclofenac (ACS-15) exhibited augmented anti-inflammatory activity against LPS-induced inflammation in comparison with the parent drug, which could be due to: 1) enhanced ability of S-diclofenac to inhibit LPS-induced upregulation of iNOS expression, 2) NF-kB pathway suppression – the effect which was not observed in diclofenac treatment (Li et al., 2007). Liu et al. (2012) have demonstrated that H2S-releasing aspirin (ACS-14) decreased the gastric lesions formation induced by aspirin administration and restored H2S plasma level, which was substantially reduced in rats subjected to acetylsalicylic acid. Also, H2S-releasing ketoprofen (ATB-352) reduced the inflammation and concomitant bone resorption in rats in experimental model of periodontitis. This effect was accompanied by a significantly diminished incidence of gastric lesions as compared to rats pretreated with classic ketoprofen (Gugliandolo et al., 2018). In addition, Glowacka et al. (2021) reported that GI toxicity was significantly reduced during chronic treatment with ATB-352 in rats, when compared to parent drug. Furthermore, ketoprofen affected intestinal microbiome profile to much greater extent than ATB-352 and, in sharp contrast to ATB-352, required co-therapy with omeprazole to counteract detrimental alterations within GI tract. Therefore, novel H2S-releasing ketoprofen could provide improved therapeutic strategy, preventing from the necessity of co-treatment of NSAIDs with PPIs and, in consequence, further impairment of intestinal microbiome induced by PPIs.

Nevertheless, ATB-346 could be considered as the leading drug in this class. This H2S-releasing derivative of naproxen has been designed for osteoarthrititis therapy and it has been confirmed by many animal studies to be as effective as the equimolar doses of its parent drug in terms of COX-1 activity inhibition leading to decreased PGE2, biosynthesis and alleviation of inflammatory response with significantly decreased GI-toxicity (Blackler et al., 2012; Ekundi-Valentim et al., 2013; Sulaima and Wallace, 2015; Wallace and Wang, 2015; Magierowski et al., 2017; Van Dingenen et al., 2019). Interestingly, ATB-346 was shown to exert therapeutic effect reflected by the acceleration of gastric ulcers healing in contrast with its parent drug, known not only to exacerbate acute gastric mucosal lesions but also producing a delay in the ulcer healing (Magierowski et al., 2015). Noteworthy, the mechanism of therapeutic properties of this compound has been assumed to involve activation of Nrf-2/HMOX-1/CO pathway, responsible for increased endogenous CO production, since it was observed that protein expression of Nrf-2 and HMOX-1 was significantly elevated in gastric mucosa of rats administered with ATB-346 (Magierowski et al., 2017). Blackler et al. (2012) pointed out that adverse effects of NSAIDs occur especially frequently among elderly patients with co-existing health problems, while most of the studies evaluating the safety of novel drugs is conducted on healthy animals. Based on this, they compared the possible outcomes of ATB-346 and NCX-429 (NO releasing derivative of naproxen) administration among rats afflicted with arthritis, obesity, or hypertension. This study revealed that both novel compounds not only presented similar anti-inflammatory properties comparing to their parent drugs – naproxen and celecoxib, but also they did not evoke mucosal damage within GI tract, suggesting their safety and tolerability by individuals with co-morbidities (Blackler et al., 2012). Recent animal studies have also reported that ATB-346 exerts protective effect on neuroinflammation, neural cell death and brain oxidative stress and may have therapeutic potential to treat traumatic brain injury or neurodegenerative diseases such as Alzheimer’s disease (Campolo et al., 2014; Mostafa et al., 2016). Importantly, a phase I clinical trial revealed the safety and good tolerability of ATB-346 (administered in doses ranging from 25 to 2,000 mg). This observation was associated with the significantly lower risk of adverse effects, comparable to that observed in placebo group (Wallace et al., 2018). Interestingly, the plasma half-life of naproxen turned out to be substantially longer in group of patients receiving ATB-346. Recently, ATB-346 has also completed Phase II clinical trial and presented significantly lower rate of GI-tract adverse effects such as ulceration, gastroesophageal reflux, abdominal discomfort or dyspepsia when compared to naproxen (Wallace et al., 2020). Chemical structure of selected H2S-NSAIDs are presented on Figure 4.

**NOSH-NSAIDs**

Keeping in view the therapeutic properties of NO and H2S, new compounds integrating both these gaseous mediators have been developed, namely NOSH-NSAIDs. Recent reports documented the promising effects of NOSH-NSAIDs with respect to the growth inhibitory properties in various human cancer cell lines, such as colon, pancreatic, breast, lung, prostate and leukemia cancer cells (Figure 2) (Chattopadhyay et al., 2012; Kodela et al., 2012; Kodela et al., 2013; Kashfi et al., 2015; Vannini et al., 2015a; Chattopadhyay et al., 2020). Interestingly, several studies demonstrated enhanced chemopreventive potential of these novel hybrids compared with parent drugs. For instance, NOSH-ASA was more effective than ASA in HT-29 colon cancer cells (Kodela et al., 2012), whereas NOSH-naproxen (AVT219) was shown to possess improved ability in suppressing the growth of adenomatous,
epithelial, and lymphocytic cancer cell lines, as compared to naproxen (Chattopadhyay et al., 2016). Also, a study by Kodela et al. (2013) identified NOSH-naproxen as approximately 8000-fold more effective than the combination of its components in prevention from the growth of human colon cancer cells, implying a remarkable synergistic effect. A similar trend was observed with NOSH-ASA (NBS-1120), being 9000-fold more potent than the sum of its partial molecules in suppressing cell growth (Chattopadhyay et al., 2012). Furthermore, efficacy of NOSH-NSAIDs to influence cancer growth, seems to be dependent on the induction of cell cycle arrest and apoptosis, along with increase in reactive oxygen species (ROS) level, known to promote cell death (Vannini et al., 2015b). Importantly, several animal studies have shown that NOSH-ASA, NOSH-sulindac (AVT-18 A) and NOSH-naproxen, in contrast to their parent drugs, were devoid of GI complications such as ulceration and bleeding, which clearly indicates improved safety profile of these novel compounds (Kashfi, 2015; Chattopadhyay et al., 2016; Chattopadhyay et al., 2020). Additionally, Kashfi et al. (2015) have demonstrated using a rat model that administration of NOSH-sulindac was associated with decreased lipid peroxidation and increased SOD activity, being an antioxidant marker, in gastric mucosa, as compared to the parent drug sulindac.

On the other hand, NOSH-NSAIDs have also attracted attention as anti-inflammatory agents and as documented in preclinical studies using the carrageenan rat paw edema model, these novel NO and H2S releasing derivatives exerted similar or even enhanced anti-inflammatory potential than their parent compounds (Kodela et al., 2013; Fonseca et al., 2015; Kashfi, 2015; Kashfi et al., 2015). Furthermore, anti-pyretic, analgesic and anti-platelet properties of NOSH-NSAIDs were comparable to those evoked by conventional NSAIDs (Kashfi et al., 2015). However, we assume that there is a lack of the studies directly comparing these NOSH-NSAIDs not only to the parent NSAID, but also to the respective NO-NSAID and H2S-NSAID to evaluate whether combining the two gaseous molecules really brings further improvement over the single mediator-releasing NSAID.

Noteworthy, NOSH-NSAIDs have shown promising results in attenuating neuroinflammation and preventing from neuronal death in animal model of ischemic stroke (Lee et al., 2013; Ji et al., 2017). Interestingly, in a human cell model of neuroinflammation the neuroprotective activity of NOSH-ASA was remarkably more potent than NO- or H2S-releasing ASA, which is consistent with previous observation on synergistic effect of NOSH-NSAIDs (Lee et al., 2013). Thus, NOSH-NSAID may provide new strategies for the treatment of neurodegenerative disorders comprising...
Alzheimer’s disease and Parkinson’s disease. Chemical structure of selected NOSH-NSAIDs are presented on Figure 5.

**CO-Releasing Molecules**

CO is perceived to be a poisonous ‘silent killer’ gaseous molecule but it is now receiving increasing attention as an important endogenous messenger constantly produced in small amounts within human body (Wu and Wang, 2005). CO is generated by degradation of free heme to biliverdin via the enzymatic activity of heme oxygenases (HMOX) - constitutive HMOX-2 highly expressed in brain and testes, and inducible isoform HMOX-1 (which is also known as heat shock protein 32 – HSP 32), reported to be activated in response to various stressful stimuli such as LPS, inflammatory cytokines or oxidative stress and plays a crucial role in the maintenance of cellular homeostasis (Choi and Alam, 1996; Higuchi et al., 2009; Takahashi et al., 2009). The
well-known cellular targets of CO are soluble guanylyl cyclase (sGC) producing cGMP, cytochrome p-450 and other cytochromes, nitric oxide synthase (NOS), and possibly COXs (Magierowski et al., 2017; Ryter et al., 2018). Importantly, CO seems to upregulate the production of NO in remote tissues suggesting that its supplementation may represent better strategy than molecules liberating NO, which is incapable of being transported to distant targets because of its high reactivity (Motterlini and Otterbein, 2010).

Currently, more light is being shed regarding regulatory functions of CO in many systems including cardiovascular, GI and nervous systems and therapeutic effect of CO-donors on various diseases such as atherosclerosis, hypertension, diabetes, chronic pulmonary disease or gastric ulcers (Motterlini and Otterbein, 2010; Jasnos et al., 2014; Olas, 2014). There is growing data emphasizing potent anti-inflammatory and cytoprotective properties of CO, known to be dependent on multiple pathways involving mitogen-activated protein kinase (MAPK), the elevated cGMP level, the enhanced expression of antioxidant enzymes, and the downregulation of inflammatory NF-κB pathway (Figure 2) (Qin et al., 2015; Sulaieva and Wallace, 2015; Ling et al., 2018).

In the light of these discoveries, several CO-prodrugs, namely CO-releasing molecules (CORMs) were developed to provide safe, manageable way of delivering physiologically efficient quantities of exogenous CO to various tissues and organs. The range of CORMs reported so far is wide and comprises the most investigated ones [Mn2(CO)10] (CORM-1), tricarbonyldichlororuthenium (II) dimer [Ru(CO)3Cl2]2 (CORM-2) and tricarbonylchloro (glycinato)ruthenium (II) (CORM-3) (Kautz et al., 2016). Numerous animal studies have confirmed that CO released from CORMs affords gastroprotection against gastric mucosal injury induced by ethanol, ischemia/reperfusion, stress or NSAIDs and has a beneficial influence by acceleration of gastric ulcers healing (Magierowska et al., 2016; Takagi et al., 2016; Magierowski et al., 2017; Magierowska et al., 2018; Magierowska et al., 2019; Magierowska et al., 2019). What is more, Freitas et al. (2006) have documented in their mice model of acute mesenteric inflammation evoked by carrageenan administration, that dimagnese decacarbonyl DMDC, a CO donor, remarkably decreased leukocyte adhesion and migration to the inflamed tissue and this effect was reversed by a soluble guanylate cyclase (sGC) inhibitor.

Furthermore, combined administration of CORM-2 with aspirin decreased gastric lesion index, increased gastric blood flow (GBF) and attenuated gastric mucosal lipid peroxidation when compared to aspirin administered alone (Magierowski et al., 2018). In another study pretreatment with CORM-2 alleviated aspirin-induced gastric mucosal damage and this beneficial effect was partly dependent on endogenous NO synthesis, but not on H2S pathway (Magierowski et al., 2016; Magierowska et al., 2018). Interestingly, also novel metal-free organic CO-prodrug, BW-CO-111 has been reported to prevent aspirin-induced gastric damage (Bakalarz et al., 2021). Despite promising effects of combined treatment with CORMs and NSAIDs in order to limit NSAID-induced gastrotoxicity, the chemical synthesis of CO-releasing NSAIDs has not been successful and there is little data published and available on this class of prodrugs. However, the effect of CO-releasing aspirin derivative - (CO-ASS) on malignant pleural mesothelioma (MPM) cell lines was investigated and CO-ASS exerted antiproliferative effect and inhibition of Nf-κB (Zanellato et al., 2013). It was hypothesized by the authors that CO-ASS might be of benefit when used as a CO releasing NSAID novel therapeutic, nevertheless further studies are needed to confirm this theory. Chemical structure of CO-ASS is presented on Figure 6.

**CARDIOVASCULAR AND RENAL SAFETY OF GASEOUS MEDIATORS-RELEASING NSAIDS**

Despite the initial focus on GI adverse effects of NSAIDs, their deleterious impact on cardiac, vascular and renal systems has gained increasing attention, especially when coxibs were introduced and their serious cardiovascular adverse effects were detected. Subsequent studies have confirmed that the widespread use of NSAIDs may be associated with harmful cardiovascular and renal complications including hypertension, myocardial infarction, heart failure as well as acute kidney injury and chronic kidney disease (Bindu et al., 2020). Importantly, NSAIDs have been shown to counteract the effects of antihypertensive drugs, in mechanisms involving PGs biosynthesis inhibition, leading to increased arterial blood pressure (Fournier et al., 2012). Also, given that the usage of NSAIDs is known to advance among elderly patients due to multiple diseases, when at the same time renal function tends to deteriorate in age-related mechanisms, this group seems to be especially vulnerable to renal toxicity (Cabassi et al., 2020).
Cardiovascular and renal adverse effects of NSAIDs constitute therefore a serious limitation to clinical application of this class of drugs, particularly among patients with numerous comorbidities within GI tract, kidneys and cardiovascular system. On the other hand, promising results have been observed with respect to the cardiovascular and renal safety profile of gaseous mediators-releasing NSAIDs. Interestingly, these novel compounds have been even shown to afford protection against various diseases affecting cardiac, vascular and renal systems.

It has been hypothesized that NO-NSAIDs, due to the ability to release NO, could exert therapeutic effects in diseases associated with reduced NO bioavailability such as diabetes mellitus, known to induce endothelial dysfunction (Shi and Vanhoutte, 2017). Consistent with this assumption, it has been demonstrated by Pieper et al. (2002) that NO-donating aspirin NCX-4016 reduced the development of impaired endothelium-dependent relaxation in animal model of chronic diabetes mellitus. Importantly, the endothelium dysfunction has been recognized as a marker of elevated risk of atherosclerosis and cardiovascular events (Bonetti et al., 2003). Additionally, NCX-4016 administration was accompanied by a decrease in plasma isoprostanes levels, suggesting that therapeutic effect of this compound may be related to its antioxidant activity, possibly by NO-dependent reduction of lipid peroxidation. Interestingly, prolonged treatment with NCX-4016 did not induce a nitrate tolerance, which constitutes a pivotal limitation to clinical use of NO-donors such as nitrates (Pieper et al., 2002). Moreover, experiments carried out on isolated rat aortas showed that NO-NSAIDs such as NCX-4215, nitroflurbiprofen and nitroparacetamol caused dose-dependent relaxation of aortic rings precontracted with adrenaline or noradrenaline (Del Soldato et al., 1999; Keeble et al., 2001). Interestingly, this effect seemed to be endothelium-independent, because removal of endothelium even potentiated vasodilatory properties of nitroflurbiprofen, possibly due to enhanced impact on the smooth muscle cells layer (Keeble et al., 2001). Furthermore, recent animal studies have indicated that NO-NSAIDs are devoid of hypotensive side effects, known to be a common complication during nitrates therapy (Wallace et al., 1995; Fujihara et al., 1998; Keeble et al., 2001). Possible explanation could be that NO-NSAIDs liberate NO at a slower rate in comparison to standard NO donors (Wallace et al., 1995). On the other hand, interesting results have been obtained by Muscará et al. (2001) who reported that NCX-4016 significantly reduced increased arterial blood pressure in hypertensive rats, but did not affect the blood pressure in normotensive animals. Thus, considering the fact that administration of standard NSAIDs is often complicated by impairment in the efficacy of antihypertensive drugs, NCX-4016 could be promising alternative for patients with hypertension, who require prolonged NSAIDs therapy (Muscará et al., 2001). Moreover, it has been found that pretreatment with NCX-4016 resulted in significant cardioprotection in vivo in a model of acute myocardial ischemia as well as in vitro based on the model of ischemia/reperfusion myocardial injury, while control treatment with aspirin showed only little or no protection (Rossoni et al., 2000; Rossoni et al., 2001). In detail, NCX-4016 was shown to markedly reduce infarction size and to decrease plasma activity of creatine kinase, which was accompanied by a significant fall in mortality rate (Rossoni et al., 2000; Rossoni et al., 2001). In addition, chronic treatment with NCX-4016 has been demonstrated to exert anti-atherosclerotic and anti-oxidative activity in arteries of hypercholesterolemic mice (Napoli et al., 2002). On the other hand, Napoli et al. (Napoli et al., 2001) investigated the effect of NCX-4016 on the extent of restenosis after balloon angioplasty in mice with concomitant hypercholesterolemia. They revealed that NCX-4016 showed both preventive and therapeutic potency against restenosis, suggesting that it may be a novel therapeutic strategy in reducing restenosis among patients subjected to balloon angioplasty, especially those with hypercholesterolemia (Napoli et al., 2001). Importantly, NCX-4016 has also shown protective effects in a human trial conducted among patients with intermittent claudication, pathology in which physical effort induces endothelial dysfunction in ischemia/reperfusion-dependent mechanisms. NCX-4016 administered orally for four weeks, significantly prevented from the exercise-induced endothelial damage, in contrast to the standard aspirin treatment, which was devoid of such effect (Gresele et al., 2007). On the other hand, another human trial revealed that NCX-4016 markedly reversed insulin resistance and enhanced vascular response to insulin in obese insulin-resistant men (Gresele and Momi, 2006). Clearly, further studies are required to fully evaluate the clinical potential of novel NO-NSAIDs with respect to cardiovascular disorders.

It has been recently demonstrated that also CO and H_{2}S released from chemical donors may provide protection within the cardiovascular system. Numerous studies have shown that CO- and H_{2}S-releasing prodrugs exert vasodilatory and antihypertensive properties (Motterlini et al., 2002; Foresti et al., 2004; Li et al., 2008; Rossoni et al., 2010; Failli et al., 2012; Kulkarni-Chitnis et al., 2015). Rossoni et al. (2010) evaluated the efficacy of H_{2}S-releasing derivatives of aspirin (ACS-14) and salicylic acid (ACS-21) in modulation of pathological changes related to metabolic syndrome induced by glutathione (GSH) depletion in rats. ACS-14 and ACS-2 but not classic aspirin, significantly restored endothelial dysfunction in aortic tissue and markedly reduced accompanying hypertension along with hyperinsulinemia, most probably in mechanisms dependent on H_{2}S release (Rossoni et al., 2010). On the other hand, experiments carried out on healthy dogs revealed that administration with H_{2}S-releasing naproxen, ATB-346, did not produce significant change in arterial blood pressure or heart rate (Wallace et al., 2018). Similarly, phase 1 clinical trial of ATB-346 demonstrated no significant difference in blood pressure between group treated with ATB-346 and placebo control (Wallace et al., 2018). Thus, further research should shed more light into understanding the mechanisms by which H_{2}S could affect blood pressure under physiological and pathological conditions.

Interestingly, CO-releasing molecules, CORMs, have been also pointed out as potential antihypertensive agents. Preclinical studies demonstrated that treatment with CORM-3 induced
relaxation of precontracted aortic rings ex vivo, leading to significant vasodilatation with the involvement of potassium channels and guanylate cyclase activity (Motterlini et al., 2002; Foresti et al., 2004; Failli et al., 2012). Additionally, in response to CORM-3 administration, a significant decrease in blood pressure in vivo in rats has been noticed, suggesting possible use of CO-donating compounds as alternative therapy for hypertension (Foresti et al., 2004). This seems to be supported by the observation that CORMs showed efficacy to attenuate acute hypertension in animal models (Motterlini et al., 2002). Also, numerous studies have presented protective effects of H$_2$S-NSAIDs, GYY4137 as chemical donor slowly liberating H$_2$S, and CORMs against myocardial injury induced by ischemia/reperfusion (Clark et al., 2003; Guo et al., 2004; Varadi et al., 2007; Rossoni et al., 2008; Citi et al., 2018). It is also worth mentioning that in another animal study GYY4137 attenuated atherosclerotic lesions in apoE (-/-) mice, which was accompanied by a significant decrease in vascular inflammation and oxidative profile (Liu et al., 2013). This data seems to be consistent with the observation that atherosclerosis correlates with decreased vascular H$_2$S level (Liu et al., 2013). Thus, it could be of interest to determine whether H$_2$S-releasing NSAIDs could be considered as therapeutic agents against atherosclerotic vascular lesions. On the other hand, the clinical implementation of CORMs may be limited due to the risk of cardiomyopathy (Kim and Choi, 2018). Therefore, further studies are still required to fully elucidate the influence of CO released from chemical donors on cardiac tissue.

As it has been mentioned above, chronic treatment with NSAIDs also increases the risk of various forms of kidney injury and concomitant reduction in renal perfusion, secondary to decreased PGs biosynthesis (Whelton, 1999). However, gaseous mediators-releasing NSAIDs could be devoid of renal adverse effects and even exert protective activity against kidney disorders. Wallace et al. (1997) reported that administration of diclofenac to healthy or cirrhotic rats resulted in significant reduction in renal blood flow, while NO-releasing derivative of this drug did not induce such effect. Also, phase 1 clinical trial did not show any significant renal side effects among healthy subjects during therapy with H$_2$S-releasing ATB-346. Furthermore, Kodela et al. (2015) hypothesized that NOSH-aspirin may be especially promising with respect to improved renal safety profile, because both NO and H$_2$S have been recognized as protective factors within renal system. Yet, further studies may confirm and support these conclusions. On the other hand, CO-releasing CORM-A1 applied to healthy mice notably increased renal blood flow, as compared to control group (RYAN et al., 2006). Noteworthy, CORM-A1 has been shown to relax renal interlobar arteries contracted with phenylephrine and this effect was dependent on guanylate cyclase activity together with the opening of potassium channels.

### Table 1: Alterations of selected molecular targets by donors of gaseous mediators NO- H$_2$S- and CO- and NSAID prodrugs.

| Molecular target | NO donors and NO-NSAIDs | H$_2$S donors and H$_2$S-NSAIDs | CO donors and NSAIDs |
|------------------|-------------------------|-------------------------------|---------------------|
| Nrf-κB           | Downregulation Bolla et al. (2006) | Downregulation Li et al. (2007) | Downregulation Ling et al. (2018) |
| Nrf-2            | No reports              | Upregulation of Nrf-2 expression in gastric mucosa, activation of Nrf-2/HMOX-1/CO pathway Magierowski et al. (2017), Corsello et al. (2018) | Activation of Nrf-2 signaling pathway in mouse macrophages Qin et al. (2015) |
| ERK/MAPK         | Inhibition of MAPK pathway Rigas (2007) | Inhibition of MAPK pathway Guo et al. (2014) | Activation of MAPK pathway Ryter et al. (2018) |
| COXs             | COX-1 and COX-2 Downregulation Magierowski et al. (2019) | COX-2 downregulation Magierowski et al. (2017) | COX-2 downregulation Ling et al. (2018) |
| CO biosynthesis  | No reports              | Upregulation of Nrf-2/HMOX-1/CO pathway in gastric mucosa Magierowski et al. (2017) | Upregulation of HMOX-1 expression in gastric mucosa Magierowska et al. (2019) |
| H$_2$S biosynthesis | Increase in CTH activation, upregulation of H$_2$S biosynthesis in cultured aortic smooth muscle cells Zhao et al. (2001) | No reports | CBS inhibition, regulation of H$_2$S biosynthesis Glowacka et al. (2020) |
| NO biosynthesis  | iNOS inhibition Rigas (2007) | Inhibition of LPS-induced iNOS overexpression Li et al. (2007), Camprolo et al. (2014) | Endothelial NOS activation Ryter et al. (2018), Zuckerbraun et al. (2008) |
| gut microbiota   | No reports              | Facilitation of antimicrobial immunity, normalization of enteric microbiota profile Blackler et al. (2015) | Modulation of interplay between microbiota and mucosal immune system Glowacka et al. (2020) |

### Reference:

- **Whelton, P. K.** (1999). The role of cyclooxygenase inhibitors in the treatment of hypertension. *Am J Hypertens*, 12(Suppl 4), 50S-55S.
- **Rigas, G.** (2007). Activation of MAPK pathway. *Ryter et al.*
- **Magierowski, E.** (2017). Upregulation of HMOX-1 expression in gastric mucosa. *Magierowski et al.*
- **Li, Y.** (2007). Downregulation. *Ling et al.*
- **Glowacka, D.** (2020). CBS inhibition, regulation of H$_2$S biosynthesis. *Glowacka et al.*
channels (RYAN et al., 2006). In spite of the essential role in physiological processes in kidneys, gaseous mediators released from various donors have been also demonstrated to possess therapeutic properties. In detail, Fujihara et al. (1998) reported that nitrofurfluriprofen (HCT-1026) alleviated renal damage in a rat model of 5/6 kidney ablation, contrary to its parent drug, flurbiprofen. In addition, they also observed that HCT-1026 markedly ameliorated albuminuria, interstitial injury, retention of creatinine and hypertension in rats subjected to kidney ablation. In turn, Kim et al. (2020) have examined the therapeutic efficacy of CORM-3 against ischemia-reperfusion renal injury in rats. CORM-3 pretreatment significantly decreased the degree of kidney damage comparing to control group, which could be explained, at least in part, by diminished apoptotic activity evoked by this compound. Similarly, renoprotective potential of CORM-2 has been observed in a mice model of thermal injury (Kim et al., 2020). CO-releasing CORM-2 prevented granulocytes infiltration in renal tissue induced in response to thermal damage, as well as notably decreased NF-κB activation in kidney. To summarize, the numerous effects of gaseous mediators released from chemical donors, involving anti-inflammatory, anti-apoptotic and vasodilatory properties, could account for significant renoprotective action of these compounds, even offering a promising alternative in future therapies against various renal disorders.

CONCLUSIONS AND FURTHER PERSPECTIVES

Overcoming the toxicity of NSAIDs, particularly the well-known GI adverse effects, still remains a target for further studies revolving around different preventive strategies including NSAIDs conjugated with gaseous mediators as one of the most interesting and promising groups. Animal studies as well as clinical trials concerning the efficacy and safety of these novel compounds have shown encouraging results, giving a solid background to prompt the further investigation. These novel NSAIDs or NSAIDs combined with CORMs were shown to modulate several molecular pathways (Table 1).

Both NO-NSAIDs and H2S-NSAIDs but also CO donors applied in combination with NSAIDs have been proven to retain the anti-inflammatory activity of their parent drugs, however, with markedly reduced gastrototoxicity and also importantly, with reduced intestinal toxicity, both become subjects of rising clinical underestimated concern (Figure 2). The increasing awareness on the deleterious influence of NSAIDs on the intestinal homeostasis confirms the need for the development of novel strategies with diminished toxicity toward intestinal mucosa and quality of enteric microbiota. Importantly, novel gaseous mediator-releasing NSAIDs with greatly limited GI toxicity and more complex molecular activity than parent drugs could be considered to be repurposed into the GI disorders treatment, such as chronic inflammation and pre- and cancerous pathologies. Although some promising results have been achieved with respect to the gaseous mediator-releasing NSAIDs, further studies are still needed to address these interesting and emerging issues.

AUTHOR CONTRIBUTIONS

Conceptualization: MM, Writing—original draft: AD, Writing—review & editing: JW, TB, and MM, Supervision: MM, Funding acquisition: MM.

FUNDING

This work was supported by a grant provided to MM from The National Centre for Research and Development, Poland (LIDER/9/0055/L-8/16/NCBR/2017).

ACKNOWLEDGMENTS

Authors would like to thank to Monika Marcinkowska (Faculty of Pharmacy, Jagiellonian University Medical College) and to Dominik Bakalarz, MSc (Department of Physiology, Jagiellonian University Medical College) for the consultations and assistance regarding chemical structures drawing for the compounds described in the manuscript.

REFERENCES

Al-Swayeh, O. A., Clifford, R. H., Del Soldato, P., and Moore, P. K. (2000). A Comparison of the Anti-inflammatory and Anti-nociceptive Activity of Nitroaspirin and Aspirin. Br. J. Pharmacol. 129 (2), 343–350. doi:10.1038/sj.bjp.0703064

Ambrosini, M. V., Mariucci, G., Rambotti, M. G., Tantucci, M., Covarelli, C., Angelis, L. D., et al. (2005). Ultrastructural Investigations on Protective Effects of NCX 4016 (Nitroaspirin) on Macrovascular Endothelium in Diabetic Wistar Rats. J. Submicr. Cytol. Pathol. 37 (2), 205–213. http://www.ncbi.nlm.nih.gov/pubmed/16335593.

Bacchi, S., Palumbo, P., Sponta, A., and Coppodino, M. F. (2012). Clinical Pharmacology of Non-steroidal Anti-inflammatory Drugs: A Review. Aiaamc 11 (1), 52–64. doi:10.2174/187152312803476255

Bakalarz, D., Suriaki, M., Yang, X., Wójcik, D., Korbut, E., Sliwowski, Z., et al. (2021). Organic Carbon Monoxide Prodrug, BW-CO-111, in Protection against Chemically-Induced Gastric Mucosal Damage. Acta Pharmaceutica Sinica B 11 (2), 456–475. doi:10.1016/j.apsb.2020.08.005

Belotwiski, J. (2015). Hydrogen Sulfide in Pharmacology and Medicine – an Update. Pharmacol. Rep. 67 (3), 647–658. doi:10.1016/j.pharep.2015.01.005

Bindu, S., Mazumder, S., and Bandyopadhyay, U. (2020). Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Organ Damage: A Current Perspective. Biochem. Pharmacol. 180, 114147. doi:10.1016/j.bcp.2020.114147

Blacker, R., Syer, S., Bolla, M., Ongini, E., and Wallace, J. L. (2012). Gastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence. PLoS One 7 (4), e35196. doi:10.1371/journal.pone.0035196

Blacker, R. W., De Palma, G., Manko, A., Da Silva, G. J., Flannigan, K. L., Bercik, P., et al. (2015). Deciphering the Pathogenesis of NSAID Enteropathy Using Proton Pump Inhibitors and a Hydrogen Sulfide-Releasing NSAID. Am. J. Physiology-Gastrointestinal Liver Physiol. 308 (12), G994–G1003. doi:10.1152/ajpgi.00066.2015

Chemically-Induced Gastric Mucosal Damage. Acta Pharmaceutica Sinica B 11 (2), 456–475. doi:10.1016/j.apsb.2020.08.005

Belotwiski, J. (2015). Hydrogen Sulfide in Pharmacology and Medicine – an Update. Pharmacol. Rep. 67 (3), 647–658. doi:10.1016/j.pharep.2015.01.005

Bindu, S., Mazumder, S., and Bandyopadhyay, U. (2020). Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Organ Damage: A Current Perspective. Biochem. Pharmacol. 180, 114147. doi:10.1016/j.bcp.2020.114147

Blacker, R., Syer, S., Bolla, M., Ongini, E., and Wallace, J. L. (2012). Gastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence. PLoS One 7 (4), e35196. doi:10.1371/journal.pone.0035196

Blacker, R. W., De Palma, G., Manko, A., Da Silva, G. J., Flannigan, K. L., Bercik, P., et al. (2015). Deciphering the Pathogenesis of NSAID Enteropathy Using Proton Pump Inhibitors and a Hydrogen Sulfide-Releasing NSAID. Am. J. Physiology-Gastrointestinal Liver Physiol. 308 (12), G994–G1003. doi:10.1152/ajpgi.00066.2015
Qin, S., Du, R., Yin, S., Liu, X., Xu, G., and Cao, W. (2015). Nrf2 Is Essential for the Anti-inflammatory Effect of Carbon Monoxide in LPS-Induced Inflammation. *Inflamm. Res.* 64 (7), 537–548. doi:10.1007/s00011-015-0834-9

Rigas, B. (2007). Novel Agents for Cancer Prevention Based on Nitric Oxide. *Biochem. Soc. Trans.* 35 (5), 1364–1368. doi:10.1042/BST0351364

Robert, A., and Asano, T. (1977). Resistance of Germfree Rats to Indomethacin-Induced Intestinal Lesions. *Prostaglandins* 14 (2), 333–341. doi:10.1016/0090-6980(77)90178-2

Rolando, B., Lazzarato, L., Donnola, M., Marino, E., Joseph, S., Morini, G., et al. (2013). Water-Soluble Nitric-Oxide-Releasing Acetylsalicylic Acid (ASA) Prodrugs. *Chem.MedChem* 8 (7), 1199–1209. doi:10.1002/cmdc.201300105

Rossoni, G., Berti, M., Colonna, V. D., Bernareggi, M., Del Soldato, P., and Berti, F. (2000). Myocardial Protection by the Nitroderivative of Aspirin, NCX 4016: In Vitro and In Vivo Experiments in the Rabbit. * Ital. Heart J.* 1 (2), 146–155. http://www.ncbi.nlm.nih.gov/pubmed/10736016.

Rossoni, G., Manfredi, B., Colonna, V. D., Bernareggi, M., and Berti, F. (2001). The Nitroderivative of Aspirin, NCX 4016, Reduces Infarct Size Caused by Myocardial Ischemia-Reperfusion in the Anesthetized Rat. *J. Pharmacol. Exp. Ther.* 297 (1), 380–387. http://www.ncbi.nlm.nih.gov/pubmed/11259566.

Qin, S., Du, R., Yin, S., Liu, X., Xu, G., and Cao, W. (2015). Nrf2 Is Essential for the Anti-inflammatory Effect of Carbon Monoxide in LPS-Induced Inflammation. *Inflamm. Res.* 64 (7), 537–548. doi:10.1007/s00011-015-0834-9

Qin, S., Du, R., Yin, S., Liu, X., Xu, G., and Cao, W. (2015). Nrf2 Is Essential for the Anti-inflammatory Effect of Carbon Monoxide in LPS-Induced Inflammation. *Inflamm. Res.* 64 (7), 537–548. doi:10.1007/s00011-015-0834-9

Srinivasan, A., and De Cruz, P. (2017). Review Article: a Practical Approach to theClinical Management of NSAID Enteropathy. *Scand. J. Gastroenterol.* 54 (1), 24–31. doi:10.1080/00315555.2016.1189546

Taihakashi, T., Shimizu, H., Morimatsu, H., Maeshima, K., Inoue, K., Agaki, R., et al. (2009). Heme Oxygenase-1 Is an Essential Cytoprotective Component in Oxidative Tissue Injury Induced by Hemorrhagic Shock. *J. Clin. Biochem. Nutr.* 44 (1), 28–40. doi:10.3748/jcbn.08-210-HO

Takeuchi, K., Ukawa, H., Konaka, A., Kitamura, M., and Sugaya, Y. (1998). Effect of Nitric Oxide-Releasing Aspirin Derivative on Gastric Functional and Ulcerogenic Responses in Rats: Comparison with Plain Aspirin. *J. Pharmacol. Exp. Ther.* 286 (1), 115–121. http://www.ncbi.nlm.nih.gov/pubmed/9655849.

Takeuchi, K., Mizoguchi, H., Araki, H., Komoike, Y., and Suzuki, K. (2001). Lack of Gastric Toxicity of Nitric Oxide-Releasing Indomethacin, NCX-530, in Experimental Animals. *Dig. Dis. Sci.* 46 (8), 1805–1818. doi:10.1023/a:1010638528675

Topol, E. J. (2005). Arthritis Medicines and Cardiovascular Events-‘House of Coxibs’. *JAMA* 293 (3), 366. doi:10.1001/jama.293.3.366

Van Dingenen, J., Pieters, L., Vral, A., and Lefebvre, R. A. (2019). The H2S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H2S Donor GY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus. *Front. Pharmacol.* 10, 116–116. doi:10.3389/fphar.2019.00116

Vannini, F., Koda, R., Chattopadhyay, M., and Kashi, K. (2015a). NOSH-aspirin Inhibits Colon Cancer Cell Growth: Effects of Positional Isomerism. *Redox Biol.* 5, 421. doi:10.1016/j.redox.2015.09.033

Vannini, F., MacKessack-Leitch, A. C., Eschbach, E. K., Chattopadhyay, M., Koda, R., and Kashi, K. (2015b). Synthesis and Anti-cancer Potential of the Positional Isomers of NOSH-Aspirin (NBS-1120) A Dual Nitric Oxide and Hydrogen Sulfide Releasing Hybrid. *Biorg. Med. Chem. Lett.* 25 (20), 4677–4682. doi:10.1016/j.bmcl.2015.08.023

Varadi, J., Lekli, I., Juhász, B., Bacsak, L., Szabo, G., Gesztelyi, R., et al. (2007). Beneficial Effects of Carbon Monoxide-Releasing Molecules on Post-ischemic Myocardial Recovery. *Life Sci. 80 (17), 1619–1626. doi:10.1016/j.lfs.2007.01.047

Varga, Z., Sabewaraii, S. r. a., and Vargova, V. (2017). Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs: An Under-recognized Public Health Issue. *Cureus* 9 (4), e1144. doi:10.7759/cureus.1144

Wallace, J. L., Elliott, S. N., Del Soldato, P., McKechnie, W., Sannicolo, F., and Cirino, G. (1997). Gastrointestinal-sparing Anti-inflammatory Drugs: The Development of Nitric Oxide-Releasing NSAIDs. *Drug Dev. Res.* 42 (3-4), 144–149. doi:10.1002/(SICI)1097-0022(19971122)3-4::AID-DDR3-5-0.CO;2-Q

Wallace, J. L., Caliendo, G., Santagada, V., Cirino, G., and Fiorucci, S. (2007). Gastrointestinal Safety and Anti-inflammatory Effects of a Hydrogen Sulfide-Releasing Diflacenol Derivative in the Rat. *Gastroenterology* 132 (1), 261–271. doi:10.1053/j.gastro.2006.11.042

Wallace, J. L., Ibarro, A., and de Nucci, G. (2017). Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury. *Dig. Dis. Sci.* 62 (9), 2223–2230. doi:10.1007/s10620-017-4681-0

Wallace, J. L., McKnight, W., Del Soldato, P., Baydoun, A. R., and Cirino, G. (1995). Anti-thrombotic Effects of a Nitric Oxide-Releasing, Gastro-Sparing Aspirin Derivative. *J. Clin. Invest.* 96 (6), 2711–2718. doi:10.1172/JCI118338

Wallace, J. L. (2013). Mechanisms, Prevention and Clinical Implications of Nonsteroidal Anti-inflammatory Drug-Enteropathy. *Wig* 19 (12), 1861. doi:10.3748/wig.v19.i12.1861

Wallace, J. L., Muscara, M. N., McKnight, W., Del Soldato, P., and Cirino, G. (1999). Gastrointestinal-sparing Anti-inflammatory Drugs: An Under-recognized Public Health Issue. *Cureus* 9 (4), e1144. doi:10.7759/cureus.1144

Wallace, J. L., Ianaro, A., and de Nucci, G. (2017). Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury. *Dig. Dis. Sci.* 62 (9), 2223–2230. doi:10.1007/s10620-017-4681-0

Wallace, J. L., McKnight, W., Del Soldato, P., Naydoun, A. R., and Cirino, G. (1995). Anti-thrombotic Effects of a Nitric Oxide-Releasing, Gastro-Sparing Aspirin Derivative. *J. Clin. Invest.* 96 (6), 2711–2718. doi:10.1172/JCI118338

Wallace, J. L. (2013). Mechanisms, Prevention and Clinical Implications of Nonsteroidal Anti-inflammatory Drug-Enteropathy. *Wig* 19 (12), 1861. doi:10.3748/wig.v19.i12.1861
Wallace, J. L. (2012). NSAID Gastropathy and Enteropathy: Distinct Pathogenesis Likely Necessitates Distinct Prevention Strategies. *Br. J. Pharmacol.* 165 (1), 67–74. doi:10.1111/j.1476-5381.2011.01509.x

Wallace, J. L. (2010). Physiological and Pathophysiological Roles of Hydrogen Sulfide in the Gastrointestinal Tract. *Antioxid. Redox Signaling* 12 (9), 1125–1133. doi:10.1089/ars.2009.2900

Wallace, J. L. (2008). Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn’t the Stomach Digest Itself? *Physiol. Rev.* 88 (4), 1547–1565. doi:10.1152/physrev.00004.2008

Wallace, J. L., Syer, S., Denou, E., de Palma, G., Vong, L., McKnight, W., et al. (2011). Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis. *Gastroenterology* 141 (4), 1314–1322. doi:10.1053/j.gastro.2011.06.075

Wallace, J. L., Vaughan, D., Dicay, M., MacNaughton, W. K., and de Nucci, G. (2018). Hydrogen Sulfide-Releasing Therapeutics: Translation to the Clinic. *Antioxid. Redox Signaling* 28 (16), 1533–1540. doi:10.1089/ars.2017.7068

Wallace, J. L., and Wang, R. (2015). Hydrogen Sulfide-Based Therapeutics: Exploiting a Unique but Ubiquitous Gasotransmitter. *Nat. Rev. Drug Discov.* 14 (5), 329–345. doi:10.1038/nrd4433

Warner, T. D., Nylander, S., and Whatling, C. (2011). Anti-platelet Therapy: Cyclo-Oxygenase Inhibition and the Use of Aspirin with Particular Regard to Dual Anti-platelet Therapy. *Br. J. Clin. Pharmacol.* 72 (4), 619–633. doi:10.1111/j.1365-2123.2011.03943.x

Watanabe, T., Tanigawa, T., Nadatani, Y., Nagami, Y., Sugimori, S., Okazaki, H., et al. (2013). Risk Factors for Severe Nonsteroidal Anti-inflammatory Drug-Induced Small Intestinal Damage. *Dig. Liver Dis.* 45 (5), 390–395. doi:10.1016/j.dld.2012.12.005

Whelton, A. (1999). Nephrotoxicity of Nonsteroidal Anti-inflammatory Drugs: Physiologic Foundations and Clinical Implications. *Am. J. Med.* 106 (5), 135–24S. doi:10.1016/S0002-9343(99)00113-8

Wu, L., and Wang, R. (2005). Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications. *Pharmacol. Rev.* 57 (4), 585–630. doi:10.1124/pr.57.4.3

Zanard, R. C. O., Brancalone, V., Distrutti, E., Fiorucci, S., Cirino, G., Wallace, J. L., et al. (2006). Hydrogen Sulfide Is an Endogenous Modulator of Leukocyte-mediated Inflammation. *FASEB J.* 20 (12), 2118–2120. doi:10.1096/fj.06-6270fje

Zannello, I., Bonarrigo, I., Ravera, M., Gabano, E., Gust, R., and Osella, D. (2013). The Hexacarbonyldicobalt Derivative of Aspirin Acts as a CO-releasing NSAID on Malignant Mesothelioma Cells. *Metallomics* 5 (12), 1604. doi:10.1039/c3mt00117b

Zhao, W., Zhang, J., Lu, Y., and Wang, R. (2001). The Vasorelaxant Effect of H2S as a Novel Endogenous Gaseous KATP Channel Opener. *EMBO J.* 20 (21), 6008–6016. doi:10.1093/emboj/20.21.6008

Zuckerbraun, B. S., Chin, B. Y., Wiegel, B., Billiar, T. R., Czisimadia, E., Rao, J., et al. (2006). Carbon Monoxide Reverses Established Pulmonary Hypertension. *J. Exp. Med.* 203 (9), 2109–2119. doi:10.1084/jem.20052267

Conflict of Interest: JW was employed by Antibe Therapeutics, Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Danielak, Wallace, Bezozowski and Magierowski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.